Ian Battersby: Is patience always a virtue?

The results of the Patient Capital Review are eagerly anticipated by tax-advantaged product providers, advisers and investors alike but, at the present time, there is very little clarity about what might emerge. The range of outcomes could be almost anything. But whatever rules are changed - presuming they must be - how are financial advisers expected to embrace them in a way that could deliver the impact the review is after? For starters, the very nature of tax-efficient investment makes it irrelevant for the large majority of investors, for whom it simply is not appropriate on groun...